GlassScriptPhysician profile
Janet Epstien
NPI 1851541932
$8,578.66
in general payments reported to CMS, 2019-2025
28 companies · $1,750 in 2025
The $1,750 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,252 · 2022: $2,023 · 2023: $1,848 · 2024: $1,706 · 2025: $1,750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,204 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,203.59 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,806.59 | 2021-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $1,419.47 | 2021-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Genzyme Corporation | $1,042.01 | 2021-2025 | |
| Csl Behring | $570.14 | 2022-2025 | Haegarda, Kcentra, Andembry |
| Regeneron Healthcare Solutions, INC. | $516.94 | 2021-2025 | Dupixent |
| Kaleo, INC. | $408.28 | 2021-2024 | Auvi-Q |
| Abbvie INC. | $404.36 | 2022-2024 | |
| Incyte Corporation | $259.68 | 2021-2024 | Opzelura |
| Novartis Pharmaceuticals Corporation | $239.52 | 2021-2025 | |
| Optinose US, INC. | $229.77 | 2021-2025 | |
| Amgen INC. | $202.04 | 2021-2024 | Otezla, Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $197.26 | 2021-2025 | Hyqvia |
| Leo Pharma INC. | $177.63 | 2023-2025 | Adbry |
| Teva Pharmaceuticals USA, INC. | $165.36 | 2021 | |
| Lilly USA, LLC | $129.53 | 2024-2025 | Ebglyss |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $123.99 | 2021-2025 | |
| Pfizer INC. | $121.99 | 2021-2022 | |
| Hikma Pharmaceuticals USA | $94.37 | 2023-2024 | Ryaltris |
| Grifols USA, LLC | $93.99 | 2022-2024 | Xembify |
| Octapharma USA, INC. | $79.92 | 2021 | |
| Pharming Healthcare, INC. | $60.14 | 2023 | Ruconest |
| Ionis Pharmaceuticals, INC. | $47.59 | 2025 | Dawnzera |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.57 | 2022-2023 | Stiolto Respimat, Spiriva Respimat |
| Phadia US INC. | $40.32 | 2025 | Immunocap |
| Eyevance Pharmaceuticals LLC | $39.71 | 2021 | |
| Aimmune Therapeutics, INC. | $30.50 | 2022 | |
| Alk-Abello, INC | $30.24 | 2021 | |
| Organon LLC | $4.75 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janet Epstien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.